CINECA IRIS Institutional Research Information System

BERRUTI, Alfredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.894
EU - Europa 5.968
AS - Asia 2.613
SA - Sud America 116
AF - Africa 95
OC - Oceania 89
Continente sconosciuto - Info sul continente non disponibili 10
Totale 16.785
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.677
CN - Cina 1.436
IT - Italia 962
IE - Irlanda 745
SE - Svezia 713
DE - Germania 650
FR - Francia 600
UA - Ucraina 572
FI - Finlandia 437
KR - Corea 389
GB - Regno Unito 304
PL - Polonia 223
AT - Austria 195
VN - Vietnam 179
CA - Canada 177
JP - Giappone 161
IN - India 138
ES - Italia 114
AU - Australia 83
DK - Danimarca 69
BR - Brasile 68
NL - Olanda 67
TR - Turchia 63
BE - Belgio 60
SG - Singapore 58
RU - Federazione Russa 56
SN - Senegal 50
HK - Hong Kong 40
HU - Ungheria 39
CH - Svizzera 35
TW - Taiwan 35
MX - Messico 33
GR - Grecia 25
TH - Thailandia 24
AR - Argentina 19
EG - Egitto 18
IR - Iran 17
PT - Portogallo 17
NO - Norvegia 15
CL - Cile 14
CZ - Repubblica Ceca 12
PH - Filippine 12
PK - Pakistan 10
RO - Romania 10
SA - Arabia Saudita 10
EU - Europa 9
ID - Indonesia 9
UZ - Uzbekistan 8
BG - Bulgaria 7
HR - Croazia 7
MK - Macedonia 7
MY - Malesia 7
DZ - Algeria 6
EC - Ecuador 6
NZ - Nuova Zelanda 6
RS - Serbia 6
ZA - Sudafrica 6
MU - Mauritius 5
PE - Perù 5
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
CO - Colombia 4
LB - Libano 4
IL - Israele 3
KE - Kenya 3
LV - Lettonia 3
MA - Marocco 3
SI - Slovenia 3
GT - Guatemala 2
JM - Giamaica 2
JO - Giordania 2
KW - Kuwait 2
LT - Lituania 2
MM - Myanmar 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
ET - Etiopia 1
IM - Isola di Man 1
IQ - Iraq 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MC - Monaco 1
MT - Malta 1
NG - Nigeria 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
Totale 16.785
Salva come PNG Salva come JPEG
Città #
Chandler 1.006
Beijing 1.004
Dublin 697
Houston 673
Ann Arbor 536
Fairfield 373
Villeurbanne 373
Jacksonville 313
Ashburn 264
Princeton 250
Wilmington 230
Medford 226
Nyköping 209
Woodbridge 203
Warsaw 202
Vienna 191
Redwood City 185
Dearborn 180
Seattle 152
Torino 137
Fremont 133
Cambridge 132
Boston 118
Dong Ket 112
Pisa 108
Milan 89
Toronto 61
New York 58
Guangzhou 55
Shanghai 51
Tokyo 46
Brescia 44
Boardman 41
San Diego 38
Turin 37
Norwalk 34
Nanjing 33
Verona 33
Falls Church 29
Brussels 28
Menlo Park 27
Rome 27
Hangzhou 26
Seoul 26
Munich 25
Chengdu 24
Lachine 24
London 24
Pune 24
Budapest 23
Helsinki 23
Madrid 22
Phoenix 22
Düsseldorf 21
Hefei 21
Mountain View 21
Taipei 21
Jinan 20
Kunming 18
Moscow 18
Paris 18
Washington 18
Chicago 16
Istanbul 16
Los Angeles 16
Shenyang 16
Amsterdam 15
Barcelona 15
Central 15
Hanoi 14
Sydney 14
Zhengzhou 14
Columbus 13
São Paulo 13
Duncan 12
Monash 12
Ottawa 12
Rochester 12
Tappahannock 12
Bethesda 11
Central District 11
Montréal 11
Naples 11
Silver Spring 11
Detroit 10
Pittsburgh 10
Szekszárd 10
Vancouver 10
Zurich 10
Bengaluru 9
Canberra 9
Gent 9
Hebei 9
Ankara 8
Athens 8
Bangkok 8
Bologna 8
Buenos Aires 8
Lyon 8
Melbourne 8
Totale 9.611
Salva come PNG Salva come JPEG
Nome #
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. 622
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain 584
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients 528
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 398
Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy. 375
Restless Legs Syndrome as a Cause of Sleep Disturbances in Cancer Patients Receiving Chemotherapy 356
ENSAT registry-based randomized clinical trials for adrenocortical carcinoma 335
Management of adjuvant mitotane therapy following resection of adrenal cancer. 302
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. 294
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome 263
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. 253
Quality of Life, Anxiety and Depression in Soft Tissue Sarcomas as Compared to More Common Tumours: An Observational Study 230
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease 214
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 200
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen 170
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis 166
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. 160
Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study 154
Pros-IT CNR: an Italian prostate cancer monitoring project 146
Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. 146
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 144
CIRCADIAN RHYTHM OF BONE TURNOVER MARKERS INBREAST CANCER PATIENTS WITH METASTATIC BONE DISEASE ANDIN CONTROL SUBJECTS 140
Enzalutamide in prostate cancer after chemotherapy. 140
Prevalence of complementary/alternative medicines (CAMs) in a cancer population in northern Italy receiving antineoplastic treatments and relationship with quality of life and psychometric features. 134
A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients 130
Adjunctive treatment of adrenocortical carcinoma 127
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 126
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 119
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. 118
THE ROLE OF HEMOGLOBIN LEVEL IN PREDICTING THE RESPONSE TO FIRST-LINE CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER (ACC) PATIENTS 117
Stage IB malignant thymoma in a Lynch syndrome patient with multiple cancers: response to incidental administration of oxaliplatin and 5-fluorouracil 113
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 108
Confronto tra due metodi per la misura della concentrazione della cromogranina A circolante in pazienti con iperplasia prostatica benigna e adenocarcinoma prostatico 103
Efficacia del reintervento chirurgico in pazienti con carcinoma del cortico-surrene recidivo 101
La recidiva di carcinoma del cortico-surrene:trattamento chirurgico o chemioterapico? 101
Adjuvant mitotane treatment: a prospective experience at the San luigi Hospital, University of Turin, Italy, USA, 2008 100
Chromogranine A serum levels in patients affected by prostate cancer and benign prostate hypertrophy: comparison between two different commercial kits 99
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer 99
Efficacy of repeat surgery in patients with recurrent adrenocortical cancer (ACC) 97
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma 96
A prospective study on adjuvant mitotane 95
A randomized comparison of high dose epirubicin versus high dose epirubicin plus lonidamine in advanced breast cancer patients. First results from a cooperative group study 95
Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. 93
Case-control study of the impact of adjuvant hormone therapy in prostate cancer patients on quality of life, anxiety and depression and self body image perception 93
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† 93
Circadian rhythm of breakthrough cancer pain. 92
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial. 91
Melatonin and human cancer. 90
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer 90
The San Luigi hospital experience with adjuvant mitotane treatment in patients with adrenocortical cancer following radical resection 84
A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. 2012 Apr 1;3(4):819-824. Epub 2012 Jan 16. PubMed Central PMCID: PMC3362404. 84
Distúrbio Pós-Traumático de Stress, qualidade do sono, ansiedade, depressão e qualidade de vida em pacientes oncológicos em tratamento quimioterápico 84
Acute myeloblastic leukemia associated with mediastinal nonseminomatous germ cell tumors. Report on two cases. 83
Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia 81
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients 81
Adjuvant mitotane in adrenocortical carcinoma - Reply 79
Does nephrectomy during adrenalectomy for adrenal cancer improve oncological results? 79
PROGNOSTIC ROLE OF SERUM TESTOSTERONE LEVELS IN PROSTATE CANCER PATIENTS DURING ANDROGEN-DEPRIVATION THERAPY 79
Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer. 79
Prevention of nausea and vomiting in cisplatin-treated patients by a selective 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930. 78
Biochemical picture of bone metabolism in breast cancer patients with bone metastases. 78
Cytotoxic effect of trabectedin in human adrenocortical carcinoma cell lines and primary cells 77
Progression of vertebral fractures in patients with adrenocortical carcinoma undergoing mitotane therapy 77
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. 75
Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. 74
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. 73
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 73
Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer 71
Background to and management of treatment-related bone loss in prostate cancer. 70
Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome 70
Development and validation of a patient-physician relationship index in the advanced cancer setting 70
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. 68
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. 68
A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbA phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine 67
THE ONSET OF SKELETAL COMPLICATIONS IN HORMONEREFRACTORY PROSTATE CANCER PATIENTS IS NOT INFLUENCEDBY THE DURATION OF ANDROGEN DEPRIVATION THERAPY 67
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. 66
Risk of depressive events in long-term surviving patients affected by hormone-related cancer according to time after diagnosis 66
Cytotoxic chemotherapy for adrenocortical carcinoma. 66
PALLIATIVE CARE PATIENTS HAD A CIRCADIAN RHYTHMICITY IN THEIR BREAKTHROUGH PAIN (BTP) EPISODES 66
Restless legs syndrome and its relationship with anxiety, depression, and quality of life in cancer patients undergoing chemotherapy 65
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. 65
Efficacia del reintervento chirurgico in pazienti con carcinoma del cortico-surrene recidivo 63
Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas 63
Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer 62
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. 62
Advances in pancreatic neuroendocrine tumor treatment. 62
The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC) 62
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 62
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly 61
Emerging drugs for adrenocortical carcinoma 61
Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy 61
Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects 61
Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy 61
Expression analysis of genes involved in DNA repair or synthesis in mixed neuroendocrine/nonneuroendocrine carcinomas 60
Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. 59
The neuroendocrine phenotype in prostate cancer: basic and clinical aspects 59
Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P). 58
Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review. 58
Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. 57
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, cremona, Italy (2010) 57
Totale 12.552
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.573
article - articoli 0
book - libri 0
conference - conferenze 5.701
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.274
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019720 0 0 0 0 0 0 0 0 0 168 394 158
2019/20202.789 134 120 174 326 232 577 336 161 252 204 170 103
2020/20211.980 172 111 176 91 161 94 249 126 219 186 112 283
2021/20222.569 100 91 110 402 167 126 220 135 75 120 452 571
2022/20233.220 397 297 85 296 255 802 257 210 299 63 166 93
2023/20241.145 203 243 104 95 72 183 45 80 27 93 0 0
Totale 17.463